A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study

BACKGROUND: Temozolomide offers minimal benefit in patients with glioblastoma with unmethylated O(6)-methylguanine-DNA methyltransferase (MGMT) promoter status, hence, the need for novel therapies. This study evaluated whether veliparib, a brain-penetrant poly(ADP-ribose) polymerase (PARP) inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Sim, Hao-Wen, McDonald, Kerrie L, Lwin, Zarnie, Barnes, Elizabeth H, Rosenthal, Mark, Foote, Matthew C, Koh, Eng-Siew, Back, Michael, Wheeler, Helen, Sulman, Erik P, Buckland, Michael E, Fisher, Lauren, Leonard, Robyn, Hall, Merryn, Ashley, David M, Yip, Sonia, Simes, John, Khasraw, Mustafa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485443/
https://www.ncbi.nlm.nih.gov/pubmed/33984151
http://dx.doi.org/10.1093/neuonc/noab111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485443/
https://www.ncbi.nlm.nih.gov/pubmed/33984151
http://dx.doi.org/10.1093/neuonc/noab111

Ejemplares similares